Advanced Solid Tumor Clinical Trial
Official title:
An Open-label, Multicenter, Dose Escalation and Expansion Phase 1/2a Study to Evaluate the Safety, Tolerability and Pharmacokinetics, and Therapeutic Activity of GI-102 in Patients With Advanced or Metastatic Solid Tumors
The purpose of this study is to evaluate the safety, tolerability, pharmacokinetics, and therapeutic activity of GI-102 as a single agent over a range of advanced and/or metastatic solid tumors.
Status | Recruiting |
Enrollment | 92 |
Est. completion date | June 30, 2025 |
Est. primary completion date | April 30, 2025 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 18 Years and older |
Eligibility | Key Inclusion Criteria: - Males and females aged = 18 years (or = 19 years according to local regulatory guidelines) at the time of screening. - Has adequate organ and marrow function as defined in protocol. - Measurable disease as per RECIST v1.1. - ECOG performance status 0-1. - Adverse events related to any prior chemotherapy, radiotherapy, immunotherapy, other prior systemic anti-cancer therapy, or surgery must have resolved to Grade =1, except alopecia and Grade 2 peripheral neuropathy. - HIV infected patients must be on anti-retroviral therapy (ART) and have a well-controlled HIV infection/disease as defined in protocol. Key Exclusion Criteria: - Has known active CNS metastases and/or carcinomatous meningitis. - An active second malignancy. - Has active or a known history of Hepatitis B or known active Hepatitis C virus infection. - Has active tuberculosis or has a known history of active tuberculosis. - Active or uncontrolled infections, or severe infection within 4 weeks before study treatment administration. - History of chronic liver disease or evidence of hepatic cirrhosis, except patients with liver metastasis. - Has an active autoimmune disease that has required systemic treatment in past 2 years. - Previous immunotherapies related to mode of action of GI-102. - Has a diagnosis of immunodeficiency or is receiving chronic systemic steroid therapy or any other form of immunosuppressive medications within 2 weeks prior to Cycle 1 Day 1. - Administration of prior systemic anti-cancer therapy including investigational agents within 4 weeks prior to treatment. - Radiotherapy within the last 2 weeks before start of study treatment administration, with exception of limited field palliative radiotherapy. - Administration of a live, attenuated vaccine within 4 weeks before Cycle 1 Day 1. - Known hypersensitivity to any of the components of the drug products and/or excipients of GI-102. Other protocol defined inclusion exclusion criteria may apply |
Country | Name | City | State |
---|---|---|---|
Korea, Republic of | Asan Medical Center | Seoul | |
Korea, Republic of | Samsung Medical Center | Seoul | |
Korea, Republic of | Seoul National University Hospital | Seoul | |
Korea, Republic of | Yonsei University Health System, Severance Hospital | Seoul | |
Korea, Republic of | Yonsei University Health System, Severance Hospital | Seoul | |
Korea, Republic of | St. Vincent's Hospital | Suwon | |
United States | Cleveland Clinic | Cleveland | Ohio |
United States | Mayo Clinic in Florida | Jacksonville | Florida |
United States | Mayo Clinic in Minnesota | Rochester | Minnesota |
United States | Mayo Clinic in Arizona | Scottsdale | Arizona |
Lead Sponsor | Collaborator |
---|---|
GI Innovation, Inc. |
United States, Korea, Republic of,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Other | Incidence of anti-GI-102 antibody (ADA) and neutralizing antibody (Nab) | Serum will be assessed for the presence of ADA and Nab based on the appropriate assay. | Study Day 1, assessed up to approximately 24 months | |
Other | Immunophenotyping of peripheral blood CD4+ T cells | CD4+ T cells in peripheral blood will be assessed by flow cytometry at various time points | Study Day 1, assessed up to approximately 24 months | |
Other | Immunophenotyping of peripheral blood CD8+ T cells | CD8+ T cells in peripheral blood will be assessed by flow cytometry at various time points | Study Day 1, assessed up to approximately 24 months | |
Other | Immunophenotyping of peripheral blood Treg cells | Treg cells in peripheral blood will be assessed by flow cytometry at various time points | Study Day 1, assessed up to approximately 24 months | |
Primary | Incidence and nature of Dose-Limiting Toxicity (DLTs) (dose escalation phase) | A DLT is defined as a clinically significant AE (classified according to the NCI CTCAE version 5) or significant laboratory abnormality that occur during the DLT assessment periods, during dose escalation and dose expansion, and is considered by the Investigator to be related to GI-102. | Study Day 1, assessed up to DLT period (3 weeks after treatment) | |
Primary | Incidence, nature, and severity of adverse events (AEs) and immune-related AEs (irAEs) (dose escalation phase) | An adverse event (AE) is any untoward medical occurrence in a participant administered a pharmaceutical product and which does not necessarily have to have a causal relationship with the treatment. An AE can therefore be any unfavorable and unintended sign (including an abnormal laboratory finding, for example), symptom, or disease temporally associated with the use of a pharmaceutical product, whether or not considered related to the pharmaceutical product. Preexisting conditions which worsen during a study are also considered as AEs. All AE events will be graded according to National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE) version 5.0. | Study Day 1, assessed up to approximately 24 months | |
Primary | Objective Response Rate (ORR) (dose expansion phase) | ORR is defined as the percentage of participants with investigator-assessed objective response of complete response (CR) or partial response (PR). PR was defined as at least a 30% decrease in the sum of diameters of target lesions, taking as reference the baseline sum of diameters. CR was defined as disappearance of all target and non-target lesions and normalization of tumor marker levels (as applicable to non-target lesions). | Study Day 1, assessed up to approximately 24 months | |
Secondary | Incidence and nature of Dose-Limiting Toxicity (DLTs) (dose expansion phase) | A DLT is defined as a clinically significant AE (classified according to the NCI CTCAE version 5) or significant laboratory abnormality that occur during the DLT assessment periods, during dose escalation and dose expansion, and is considered by the Investigator to be related to GI-102. | Study Day 1, assessed up to DLT period (3 weeks after treatment) | |
Secondary | Objective Response Rate (ORR) (dose escalation phase) | ORR is defined as the percentage of participants with investigator-assessed objective response of complete response (CR) or partial response (PR). PR was defined as at least a 30% decrease in the sum of diameters of target lesions, taking as reference the baseline sum of diameters. CR was defined as disappearance of all target and non-target lesions and normalization of tumor marker levels (as applicable to non-target lesions). | Study Day 1, assessed up to approximately 24 months | |
Secondary | Disease Control Rate (DCR) | DCR is defined as the percentage of patients who have achieved CR, PR and stable disease (SD), per RECIST v1.1 guideline as determined by the investigators. | Study Day 1, assessed up to approximately 24 months | |
Secondary | Duration of objective response (DoR) | DCR is defined as the time from the first occurrence of a documented objective response to the time of the first document disease progression or death from any cause, whichever occurs first, per RECIST v1.1 as determined by the investigator. | Study Day 1, assessed up to approximately 24 months | |
Secondary | Progression-free survival (PFS) | PFS is defined as the time from the first study treatment (Day 1) to the first occurrence of progression or death from any cause, whichever occurs first, per RECIST v1.1 guideline as determined by the investigator | 6-month, 12-month, and 18-month | |
Secondary | Overall survival (OS) | OS is defined as the time from the first study treatment to death from any cause | 12-month and 18-month | |
Secondary | Peak plasma concentration (Cmax) of GI-102 | Based on the concentration vs time profile by dose level | Study Day 1, assessed up to approximately 24 months | |
Secondary | Half-life of GI-102 (T1/2) | Based on the concentration vs time profile by dose level | Study Day 1, assessed up to approximately 24 months | |
Secondary | Area under the plasma concentration versus time curve (AUC) of GI-102 | Based on the concentration vs time profile by dose level | Study Day 1, assessed up to approximately 24 months | |
Secondary | Clearance of GI-102 | Based on the concentration vs time profile by dose level | Study Day 1, assessed up to approximately 24 months | |
Secondary | Volume of distribution (Vd) of GI-102 after administration | Based on the concentration vs time profile by dose level | Study Day 1, assessed up to approximately 24 months |
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT06223308 -
A Study Evaluating the Safety and Efficacy of HB0028 in Subjects With Advanced Solid Tumors
|
Phase 1/Phase 2 | |
Not yet recruiting |
NCT05515185 -
B7-H3 Targeting CAR-T Cells Therapy for B7-H3 Positive Solid Tumors
|
Early Phase 1 | |
Completed |
NCT05508100 -
Dose Confirmation and Dose Expansion Phase 1 Study of IO-108 and IO-108 + Anti-PD-1 in Solid Tumors
|
Phase 1 | |
Recruiting |
NCT05094804 -
A Study of OR2805, a Monoclonal Antibody Targeting CD163, Alone and in Combination With Anticancer Agents
|
Phase 1/Phase 2 | |
Completed |
NCT02836600 -
A Study of LY3039478 in Japanese Participants With Advanced Solid Tumors
|
Phase 1 | |
Recruiting |
NCT04890613 -
Study of CX-5461 in Patients With Solid Tumours and BRCA1/2, PALB2 or Homologous Recombination Deficiency (HRD) Mutation
|
Phase 1 | |
Recruiting |
NCT04390737 -
Evaluate the Safety and Clinical Activity of HH2853
|
Phase 1/Phase 2 | |
Recruiting |
NCT05981703 -
A Study Investigating BGB-26808 Alone or in Combination With Tislelizumab in Participants With Advanced Solid Tumors
|
Phase 1 | |
Recruiting |
NCT06007482 -
A Study of ES009 in Subjects With Locally Advanced or Metastatic Solid Tumors
|
Phase 1 | |
Completed |
NCT04108676 -
Effect of Omeprazole on PK of Fluzoparib in Healthy Male Subjects
|
Phase 1 | |
Recruiting |
NCT05798611 -
Study of ART0380 in Patients With Biologically Selected Solid Tumors
|
Phase 2 | |
Recruiting |
NCT05076396 -
PM14 Administered Intravenously to Patients With Advanced Solid Tumors
|
Phase 1 | |
Recruiting |
NCT06054932 -
Safety, Tolerability, and Immunogenicity of LK101 Alone in Participants With Incurable Solid Tumors
|
Phase 1 | |
Recruiting |
NCT06008366 -
A Phase 1/2 Study of 7MW3711 in Advanced Solid Tumors
|
Phase 1/Phase 2 | |
Recruiting |
NCT04825392 -
A Phase Ib Study of HX008 in Patients With Advanced Solid Tumors
|
Phase 1 | |
Active, not recruiting |
NCT04242199 -
Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of INCB099280 in Participants With Advanced Solid Tumors
|
Phase 1 | |
Not yet recruiting |
NCT06365918 -
Study of VG2025 Delivered Intraperitoneally in Patients With Advanced Solid Tumors With Carcinomatosis
|
Phase 1 | |
Recruiting |
NCT05443126 -
A Study of EP0031 in Patients With Advanced RET-altered Malignancies
|
Phase 1/Phase 2 | |
Recruiting |
NCT05461287 -
Safety, Tolerability and Pharmacokinetics Study of QLS31904 in Patients With Advanced Solid Tumors
|
Phase 1 | |
Recruiting |
NCT05569057 -
A Phase I Trial of SIM1811-03 in Subjects With Advanced Solid Tumors and Cutaneous T-cell Lymphoma
|
Phase 1 |